GYRE GYRE THERAPEUTICS, INC.
Price Chart
Executive Summary
Gyre Therapeutics filed an 8-K furnishing an updated corporate investor presentation. The presentation highlights the company's pipeline following the Cullgen acquisition, including positive Phase 3 data for F351 (hydronidone) in CHB-associated liver fibrosis (52.85% fibrosis regression vs 29.84% placebo, p=0.0002) with NDA accepted by China's NMPA in May 2026, and early-stage clinical data for CG001419 (TRK degrader) showing no DLTs in 22 patients. No new financial guidance or material financial data was provided.
Actionable Insight
This is a routine pipeline update with no new financial data. The F351 NDA acceptance in China is a positive regulatory milestone but was previously disclosed. Monitor for NMPA approval decision on F351 and initiation of US Phase 2 for MASH in 2027. The CG001419 safety data is early but encouraging for the pain program.
Key Facts
- F351 Phase 3 trial met primary endpoint: 52.85% 1-stage fibrosis regression at Week 52 vs 29.84% placebo (p=0.0002)
- F351 NDA accepted by China NMPA in May 2026 with Breakthrough Therapy Designation and Priority Review
- CG001419 Phase 1a data from first 22 patients showed no DLTs, treatment-related SAEs, or Grade 3 treatment-related AEs
- CG009301 Phase 1 dose escalation underway; first 8 patients showed no DLTs
- CDK2-Cyclin E degrader (CG923308) IND anticipated Q1 2027
- Company has ~740 employees worldwide with operations in San Diego, Shanghai, and Beijing
- No financial results, guidance, or material financial data were disclosed in this filing
Financial Impact
No financial figures disclosed; filing is a routine corporate presentation update
Risk Factors
- F351 approval and commercialization in China subject to regulatory and competitive risks
- All pipeline candidates are in early to mid-stage development with no guarantee of clinical or regulatory success
- Reliance on China operations introduces geopolitical and operational risks
- No new financial data to assess cash runway or revenue trajectory
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-023625 |
| Document: ef20075381_8k.htm | 0001140361-26-023625 |
| Document: 0001140361-26-023625-index-headers.html | 0001140361-26-023625 |
| Document: 0001140361-26-023625-index.html | 0001140361-26-023625 |
| Document: 0001140361-26-023625.txt | 0001140361-26-023625 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
14d ago
|
8-K
| $5.56 $6.13 | ▲ +10.25% | ▲ +13.22% | $5.82 (+4.68%) |
|
May 14, 2026
4w ago
|
8-K
| $6.55 $6.06 | ▼ −7.48% | ▼ −8.44% | $5.82 (−11.15%) |
|
May 4, 2026
6w ago
|
8-K / DEFA14A
| $7.92 $7.09 | ▼ −10.48% | ▼ −13.42% | $5.82 (−26.52%) |
|
May 4, 2026
6w ago
|
Press Release
| $7.92 $7.09 | ▼ −10.48% | ▼ −13.42% | $5.82 (−26.52%) |
|
Mar 12, 2026
13w ago
|
8-K
| $7.81 $6.80 | ▼ −12.93% | ▼ −11.95% | $5.82 (−25.48%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $7.81 $6.80 | ▼ −12.93% | ▼ −11.95% | $5.82 (−25.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access